| HOME | HELP | CONTACT US | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
© 2004 AlphaMed Press
Monoclonal Antibodies, Small Molecules, and Vaccines in the Treatment of Breast Cancer
The University of Texas, M.D. Anderson Cancer Center, Houston, Texas, USA
Correspondence: Francisco J. Esteva, M.D., Ph.D., Department of Breast Medical Oncology, The University of Texas, M.D. Anderson Cancer Center, 1515 Holcombe Boulevard, Unit 424, Houston, Texas 77030-4009, USA. Telephone: 713-792-2817; Fax: 713-745-5768; e-mail: festeva{at}mdanderson.org
The human epidermal growth factor receptor (HER, ErbB) family of receptors is considered an important therapeutic target, and various types of molecularly based small molecules, including monoclonal antibodies, protein tyrosine kinase inhibitors, and therapeutic vaccines, are in development as potential therapies for metastatic breast cancer. Trastuzumab (Herceptin®; Genentech, Inc.; South San Francisco, CA), the first approved monoclonal antibody for HER-2 (ErbB-2)-overexpressing metastatic breast cancer, provided the proof of principle that targeting specific receptors results in clinical benefit. Other monoclonal antibodies and the small molecule dual protein tyrosine kinase inhibitors show great promise as treatments for metastatic breast cancer but require evaluation in clinical trials to assess their benefits. Therapeutic vaccines may have a role, particularly in early-stage disease, but they are associated with greater limitations and study design issues that make their evaluation difficult. Optimum combination therapy regimens with a variety of novel approaches that incorporate small molecule targeted therapies need to be developed, and the population most likely to benefit from targeted therapies needs to be identified.
This article has been cited by other articles:
 |
|
 |
|
  M. M. Seavey, P. C. Maciag, N. Al-Rawi, D. Sewell, and Y. Paterson An Anti-Vascular Endothelial Growth Factor Receptor 2/Fetal Liver Kinase-1 Listeria monocytogenes Anti-Angiogenesis Cancer Vaccine for the Treatment of Primary and Metastatic Her-2/neu+ Breast Tumors in a Mouse Model J. Immunol., May 1, 2009; 182(9): 5537 - 5546. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Q. Brown, L. G. Wilke, J. Geradts, S. A. Kennedy, G. M. Palmer, and N. Ramanujam Quantitative Optical Spectroscopy: A Robust Tool for Direct Measurement of Breast Cancer Vascular Oxygenation and Total Hemoglobin Content In vivo Cancer Res., April 1, 2009; 69(7): 2919 - 2926. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. Nakagawa, H. Minami, M. Kanezaki, A. Mukaiyama, Y. Minamide, H. Uejima, T. Kurata, T. Nogami, K. Kawada, H. Mukai, et al. Phase I Dose-escalation and Pharmacokinetic Trial of Lapatinib (GW572016), a Selective Oral Dual Inhibitor of ErbB-1 and -2 Tyrosine Kinases, in Japanese Patients with Solid Tumors Jpn. J. Clin. Oncol., February 1, 2009; 39(2): 116 - 123. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 X. Huang, X. Li, and B. Guo KLF6 Induces Apoptosis in Prostate Cancer Cells through Up-regulation of ATF3 J. Biol. Chem., October 31, 2008; 283(44): 29795 - 29801. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. V. Sitkovsky, J. Kjaergaard, D. Lukashev, and A. Ohta Hypoxia-Adenosinergic Immunosuppression: Tumor Protection by T Regulatory Cells and Cancerous Tissue Hypoxia Clin. Cancer Res., October 1, 2008; 14(19): 5947 - 5952. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. Harada, R. Yasunaga, Y. Higashimura, R. Yamaji, K. Fujimoto, J. Moss, H. Inui, and Y. Nakano Glyceraldehyde-3-phosphate Dehydrogenase Enhances Transcriptional Activity of Androgen Receptor in Prostate Cancer Cells J. Biol. Chem., August 3, 2007; 282(31): 22651 - 22661. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. D. Lester, M. Jo, V. Montel, S. Takimoto, and S. L. Gonias uPAR induces epithelial mesenchymal transition in hypoxic breast cancer cells J. Cell Biol., July 24, 2007; 178(3): 425 - 436. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. K. Martens, K. M. Kirschner, C. Warnecke, and H. Scholz Hypoxia-inducible Factor-1 (HIF-1) Is a Transcriptional Activator of the TrkB Neurotrophin Receptor Gene J. Biol. Chem., May 11, 2007; 282(19): 14379 - 14388. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. W. Dewhirst, I. C. Navia, D. M. Brizel, C. Willett, and T. W. Secomb Multiple Etiologies of Tumor Hypoxia Require Multifaceted Solutions Clin. Cancer Res., January 15, 2007; 13(2): 375 - 377. [Full Text] [PDF]
|
|
|
|
 |
|
 G. Curigliano, G. Spitaleri, E. Pietri, M. Rescigno, F. de Braud, A. Cardillo, E. Munzone, A. Rocca, G. Bonizzi, V. Brichard, et al. Breast cancer vaccines: a clinical reality or fairy tale? Ann. Onc., May 1, 2006; 17(5): 750 - 762. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. E. Hardee, M. O. Arcasoy, K. L. Blackwell, J. P. Kirkpatrick, and M. W. Dewhirst Erythropoietin Biology in Cancer Clin. Cancer Res., January 15, 2006; 12(2): 332 - 339. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. A. Hudis and S. Van Belle Introduction: Examining the Potential Impact of Anemia Treatment on Clinical Outcomes in Anemic Cancer Patients Oncologist, November 1, 2004; 9(suppl_5): 1 - 3. [Full Text] [PDF]
|
|
|
|
|
|
P. Vaupel The Role of Hypoxia-Induced Factors in Tumor Progression Oncologist, November 1, 2004; 9(suppl_5): 10 - 17. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F. Farrell and A. Lee The Erythropoietin Receptor and Its Expression in Tumor Cells and Other Tissues Oncologist, November 1, 2004; 9(suppl_5): 18 - 30. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. Harrison and K. Blackwell Hypoxia and Anemia: Factors in Decreased Sensitivity to Radiation Therapy and Chemotherapy? Oncologist, November 1, 2004; 9(suppl_5): 31 - 40. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. Ludwig, C. A. Hudis, G. Goss, and B. Leyland-Jones Epoetin Alfa: Future Directions and Future Research Oncologist, November 1, 2004; 9(suppl_5): 70 - 73. [Full Text] [PDF]
|
|
| HOME | HELP | CONTACT US | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| THE ONCOLOGIST | STEM CELLS | CME | ALPHAMED PRESS JOURNALS |
Copyright © 2004 by AlphaMed Press.